Revitalise Your Lymphatic System with LYMPHOGENiX
LYMPHOGENiX is a pioneer in lymphatic vessel regeneration. Our proprietary technology revitalizes lymphatic function and promotes regeneration of various medical conditions. We envision our methods to treat heart failure, pulmonary fibrosis and with substantial potential to tackle skin-ageing, obesity, Alzheimer’s Disease and infertility as well. We believe in helping patients improve their vitality, one treatment at a time.
About
LYMPHOGENiX is at the forefront of lymphatic vessel regeneration research, leveraging cutting-edge technology to develop new treatments for a variety of diseases.
Our team of experts has extensive research and industry experience in field and are highly dedicated to developing new clinical solutions. With international partnerships and the support from global stakeholders, we are confident in our ability to make a unique contribution to the field of regenerative medicine.
Services
Our Lymphatic Vessels Regeneration service portfolio is flexible and tailored solution. In addition to our core service, we also supply proprietary cytokine cocktails for skin-ageing clinics and offer pipeline management for CNS research. We collaborate with partners on clinical studies and research for infertility treatment. Our commitment to working with our stakeholders means that we are constantly improving and expanding our portfolio.
Infertility affects 1 in 6 adults, but there is hope. Research provides novel indication for infertility treatments targeting the regeneration of lymphatic vessels. Our proprietary cytokine cocktail can markedly increase lymphangiogenic effects in female reproductive organs, potentially offering therapeutic benefits against infertility.
01
Infertility treatment
Our Skin-ageing treatment is a cutting-edge solution for visible improvements of aging skin. By targeting lymphatic vessel regeneration, this treatment is more effective than traditional fibroblast treatments. We will begin by licensing our FRF (fibroblast-rejuvenating factor) to our trusted partners.
02
Skin-ageing treatment
We are proud to be at the forefront of research in Alzheimer's treatment. Our treatment is expected to improve amyloid-β clearance through lymphatic regeneration.
03
Alzheimer's Therapy
Our innovative heart failure treatment is proven to improve cardiac function by generating more lymphatic vessels than conventional methods, This technology is clinically tested and safe. The technology comes with an 8-year history of excellence inherited from a previous biotech start-up.
04
Heart Failure Treatment
Pulmonary Fibrosis
05
Pulmonary fibrosis currently does not have a cure. Our approach to pulmonary fibrosis is to recover fibrotic areas by activating lymphangiogenesis. We have three years of research into this modality and have demonstrated high therapeutic potential in non-clinical settings.
Revolutinise Lymphangiogeneic Cell Therapies
Tissue sample collected at our licensed clinic, hospitals or laboratories
Biopsy from patient or donor
1
Our core technology. Fibroblasts are stimulated by our fibroblast-rejuvenating factor (FRF) and acquire strong lymphangiogenic effects.
Rejuvenation of fibroblast
3
Fibroblast are cultured to expand at authorized & secure laboratories.
Fibroblast cell expansion
2
After essential checks, fibroblasts or the rejuvenated culture fluids are administrated via our proprietary injecting device around damaged tissue.
QC and administration
4
At LYMPHOGENiX, our unique company structure enables us to offer a range of services tailored to meet the needs of our customers. Our headquarters is based in the UK – the perfect location to drive global business development, while our innovative R&D function is based in Japan, ready to leverage the latest technology trends.
Our diverse and talented team is passionate about working together to bring cutting-edge solutions to our clients, and deliver measurable value to all people in the world.
Our Creative Founders.
I am proud to lead the team at LYMPHOGENiX, leveraging my years of expertise in stem cells and regenerative medicine. With a Ph.D. in Medicine from Tokyo Women's Medical University and experience leading a research team at Keio University, I bring a wealth of knowledge to our cutting-edge work. I was also a co-founder of Metcela Inc, where I focused on developing new treatments for heart disease. Additionally, I currently teach at Keio University, sharing my passion for regenerative medicine with the next generation of scientists.
Dr Takahiro Iwamiya
Founder / Director / Science
As the co-founder of LYMPHOGENiX, I am committed to providing the most innovative and cutting-edge solutions in the field of regenerative medicine. With over a decade of experience in global innovation management, I have developed a deep understanding of the needs of our clients. I have previously worked with companies like DefiniGEN, and I am familiar with the latest trends and advancements in the field. I'm grateful to have the opportunity to help usher in the next generation of regenerative medicine.
Dr Masashi Matsunaga
Founder / Director / Operations
Newsletter
LYMPHOGENiX established!!
Welcome to LYMPHOGENiX, the leader in regenerative medicine through lymphangiogenesis. Our R&D team is located in Japan, while our operations seeking investment are based in the UK. Launched in 2024, we are committed to global business development and advancing the field of regenerative medicine.
We are looking for investors
If you are interested in supporting LYMPHOGENiX and investing in the future of regenerative medicine, we welcome discussions to join our seed round investment opportunity. Our company is poised for growth, and we are actively seeking investors who are passionate about the field and dedicated to helping us advance our mission.
Join our global team!!
LYMPHOGENiX is a leading-edge regenerative medical company focused on developing innovative therapeutic options. As we continue to grow, we are searching for talented leaders to help guide us into the future. We are looking for experience in CXO positions, as well as business development managers and R&D scientists who are passionate about advancing the frontiers of science and technology.
R&D in Japan, operation globally from the UK
LYMPHOGENiX is leading the way in global business operations and investment management. Our R&D activities remain in Japan, where we conduct preclinical POC studies and file patents to protect our intellectual property. We believe in investing in the future by supporting entrepreneurial activities that push the boundaries of what is possible. Our team are experts committed to providing our clients with the best investment opportunities available.